- Home
- FORA vs TIL Comparison
FORA vs TIL Comparison
Compare FORA & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- TIL
- Stock Information
- Founded
- FORA 2014
- TIL 2018
- Country
- FORA United States
- TIL United States
- Employees
- FORA N/A
- TIL N/A
- Industry
- FORA Computer Software: Prepackaged Software
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- TIL Health Care
- Exchange
- FORA Nasdaq
- TIL Nasdaq
- Market Cap
- FORA 66.1M
- TIL 230.1M
- IPO Year
- FORA N/A
- TIL 2021
- Fundamental
- Price
- FORA $1.96
- TIL $28.30
- Analyst Decision
- FORA Strong Buy
- TIL Buy
- Analyst Count
- FORA 1
- TIL 5
- Target Price
- FORA $5.00
- TIL $119.00
- AVG Volume (30 Days)
- FORA 8.1K
- TIL 349.6K
- Earning Date
- FORA 08-13-2025
- TIL 08-12-2025
- Dividend Yield
- FORA N/A
- TIL N/A
- EPS Growth
- FORA N/A
- TIL N/A
- EPS
- FORA N/A
- TIL N/A
- Revenue
- FORA $22,332,001.00
- TIL N/A
- Revenue This Year
- FORA $13.31
- TIL N/A
- Revenue Next Year
- FORA $43.65
- TIL N/A
- P/E Ratio
- FORA N/A
- TIL N/A
- Revenue Growth
- FORA 5.22
- TIL N/A
- 52 Week Low
- FORA $1.85
- TIL $9.62
- 52 Week High
- FORA $4.03
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- FORA 43.34
- TIL 46.80
- Support Level
- FORA $1.95
- TIL $20.60
- Resistance Level
- FORA $2.09
- TIL $25.95
- Average True Range (ATR)
- FORA 0.10
- TIL 3.47
- MACD
- FORA -0.02
- TIL -1.29
- Stochastic Oscillator
- FORA 3.33
- TIL 22.74
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.